Compare Charles River Laboratories Intl. Inc (CRL) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Upstart Holdings Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $286.92 (market cap $13.46B), while Upstart Holdings Inc trades at $29.24 (market cap $2.91B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 4.6× Upstart Holdings Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals.
| CRL | UPST | |
|---|---|---|
Market Cap | $13.46B | $2.91B |
Sector | Health | Financials |
52-Week High | $282.00 | $73.76 |
52-Week Low | $145.57 | $24.22 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Upstart trades at $29.23, down 3.24% today, with a bearish technical signal despite recent Q2 2026 earnings beat showing 42% revenue growth and return to GAAP profitability. The stock faces valuation compression concerns with a P/E of 57.48, while analyst consensus remains divided with a $47.20 price target suggesting significant upside potential from current levels.
The outlook balances strong AI-driven loan origination growth against persistent earnings misses and negative cash flow from operations. Key risks include high short interest at 27% and sensitivity to interest rate environment, though institutional sentiment appears cautiously optimistic given the 45% buy rating distribution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
